Last reviewed · How we verify

bevacizumab, everolimus, panitumumab

Herbert Hurwitz, MD · Phase 1 active Small molecule

bevacizumab, everolimus, panitumumab is a Small molecule drug developed by Herbert Hurwitz, MD. It is currently in Phase 1 development. Also known as: avastin, RAD001.

At a glance

Generic namebevacizumab, everolimus, panitumumab
Also known asavastin, RAD001
SponsorHerbert Hurwitz, MD
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bevacizumab, everolimus, panitumumab

What is bevacizumab, everolimus, panitumumab?

bevacizumab, everolimus, panitumumab is a Small molecule drug developed by Herbert Hurwitz, MD.

Who makes bevacizumab, everolimus, panitumumab?

bevacizumab, everolimus, panitumumab is developed by Herbert Hurwitz, MD (see full Herbert Hurwitz, MD pipeline at /company/herbert-hurwitz-md).

Is bevacizumab, everolimus, panitumumab also known as anything else?

bevacizumab, everolimus, panitumumab is also known as avastin, RAD001.

What development phase is bevacizumab, everolimus, panitumumab in?

bevacizumab, everolimus, panitumumab is in Phase 1.

Related